ARTICLE | Clinical News
Sylvant siltuximab regulatory update
March 2, 2015 8:00 AM UTC
Germany’s Federal Joint Committee (G-BA) concluded that Sylvant siltuximab from Johnson & Johnson provides added benefit for patients with multicentric Castleman’s disease who are HIV-negative and human herpes virus 8 (HHV-8)-negative, the drug’s approved indication. G-BA estimated that 130-1,460 patients could benefit from the chimeric mAb against IL-6. ...